Company:  SESEN BIO, INC. (SESN)
Form Type:  8-K
Filing Date:  11/8/2019 
CIK:  0001485003 
Address:  245 FIRST STREET
SUITE 1800
 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-444-8550 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.14  
Change: 
0.00 (0.00%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$119.33M
Trade SESN now with 

© 2019  
Description of Business
We are a late-stage clinical company developing targeted fusion protein therapeutics, or TFPTs, composed of an anti-cancer antibody fragment tethered to a protein toxin for the treatment of cancer. We genetically fuse the cancer-targeting antibody fragment and the cytotoxic protein payload into a single molecule which is produced through our proprietary one-step manufacturing process. We target tumor cell surface antigens with limited expression on normal cells. Binding of the target antigen by the TFPT allows for rapid internalization into the targeted cancer cell. We have designed our targeted proteins to overcome the fundamental efficacy and safety challenges inherent in existing antibody-drug conjugates, or ADCs, where a payload is chemically attached to a targeting antibody.
Register and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02. Results of Operations and Financial Condition.
    SECTION 8 OTHER EVENTS
      Item 8.01 - Other Events.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 - Financial Statements and Exhibits.
    SIGNATURE
  EXHIBIT 99.1